(Q45639193)

14 December 2017

title

Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection (English)

1 reference

14 December 2017

7

Ann M Schmidt

1 reference

14 December 2017

Christopher P Locher

1

1 reference

14 December 2017

Stephanie A Witt

2

1 reference

14 December 2017

Brittany M Ashlock

3

1 reference

14 December 2017

Patricia Polacino

4

1 reference

14 December 2017

Shiu Lok Hu

5

1 reference

14 December 2017

Stephen Shiboski

6

1 reference

14 December 2017

Michael B Agy

8

1 reference

14 December 2017

David M Anderson

9

1 reference

14 December 2017

Silvija I Staprans

10

1 reference

14 December 2017

Jan zur Megede

11

1 reference

14 December 2017

Jay A Levy

12

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

14 December 2017

number of pages

12

1 reference

inferred from page(s)

published in

Vaccine

1 reference

14 December 2017

volume

22

1 reference

14 December 2017

issue

17-18

1 reference

14 December 2017

page(s)

2261-2272

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

14 December 2017

1 reference

Nucleic acid immunization: concepts and techniques associated with third generation vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

New hope for an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Genetic adjuvants for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Primary CD8+ cells from HIV-infected individuals can suppress productive infection of macrophages independent of beta-chemokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Codon usage limitation in the expression of HIV-1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Enhancement of antibody responses to an HIV-2 DNA envelope vaccine using an expression vector containing a constitutive transport element

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

An AIDS-like condition induced in baboons by HIV-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Baboons as an animal model for human immunodeficiency virus pathogenesis and vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Transient virus infection and pathogenesis of a new HIV type 2 isolate, UC12, in baboons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Baboons as an animal model for genetic studies of common human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Nonhuman primate models to evaluate vaccine safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Biologic heterogeneity of human immunodeficiency virus type 2 (HIV-2) strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Cloning, sequencing, and homology analysis of nonhuman primate Fas/Fas-ligand and co-stimulatory molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Molecular cloning of the human immunodeficiency virus subtype 2 strain HIV-2UC2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Superinfection with human immunodeficiency virus type 2 can reactivate virus production in baboons but is contained by a CD8 T cell antiviral response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

CD8+ cells from HIV-2-infected baboons control HIV replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

CD8+ lymphocytes suppress HIV production by autologous CD4+ cells without eliminating the infected cells from culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

CD8+ T lymphocyte control of HIV replication in cultured CD4+ cells varies among infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Evaluation of cytotoxic T-lymphocyte responses in human and nonhuman primate subjects infected with human immunodeficiency virus type 1 or simian/human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Production of baboon (Papio hamadryas) monoclonal antibodies by herpesvirus papio immortalized baboon lymph node cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

An African primate lentivirus (SIVsm) closely related to HIV-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Long-term cultivation of T-cell subsets from patients with acquired immune deficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

R: A Language for Data Analysis and Graphics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Prospects for vaccine protection against HIV-1 infection and AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Plasmid DNA induces increased lymphocyte trafficking: a specific role for CpG motifs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motif-independent manner by complex formation with cationic liposomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

HLA compatibility requirements for CD8(+)-T-cell-mediated suppression of human immunodeficiency virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

7 January 2021

Simian immunodeficiency virus-specific T-cell-mediated proliferative response of infected rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

7 January 2021

Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

7 January 2021

Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.045

7 January 2021

10.1016/J.VACCINE.2003.11.045

Identifiers

DOI

1 reference

14 December 2017

1 reference